查看購物車
  • English
  • Japanese
  • Korean
封面
市場調查報告書
商品編碼
2049219

膠質母細胞瘤多形性治療市場分析：依藥物類型、給藥途徑、分子類型、通路和地區分類（2026-2034 年）

Glioblastoma Multiforme Treatment Market Report by Drug Type, Route of Administration, Type of Molecule, Distribution Channel, and Region 2026-2034
出版日期: | 出版商: IMARC | 英文 137 Pages | 商品交期: 2-3個工作天內

價格

2025年，全球多形性膠質母細胞瘤治療市場規模達24億美元。展望未來，IMARC Group預測，該市場將從2026年到2034年以6.13%的複合年成長率成長，到2034年達到42億美元。

多形性膠質母細胞瘤（也稱為IV級星狀細胞瘤）​​是一種IV級腦瘤，可在腦細胞內迅速擴散並感染周圍細胞。其特徵是細胞快速退化，會對腦組織造成顯著壓迫，導致劇烈頭痛和癲癇發作。此疾病的確切病因尚不清楚，但包括罕見遺傳性疾病（如圖爾科症候群）在內的多種因素被認為與其相關。它是最致命的腦腫瘤之一，對治療具有高度抗藥性，導致患者確診後的生存期極短。目前的治療方法包括手術切除、化療和放射線治療。

全球腫瘤疾病發生率的不斷上升和老齡人口的成長是推動市場成長的關鍵因素。此外，針對膠質母細胞瘤幹細胞抗藥性的先進治療方法的研發也對市場成長產生了積極影響。同時，分子生物技術和基因療法在癌症及相關疾病領域的研發活動活性化，推動了各種生物製藥的開發。這些藥物有助於減輕現有治療方法的副作用，並正被越來越多的患者所接受。此外，世界各國政府為改善醫療基礎設施所做的努力以及人們對各種治療方法方案日益成長的認知，預計將進一步提振市場前景。

目錄

第1章：序言

第2章：分析的範圍與方法

  • 分析目的
  • 相關利益者
  • 數據來源
    • 主要訊息
    • 二手資訊
  • 市場估值
    • 自下而上的方法
    • 自上而下的方法
  • 分析方法

第3章執行摘要

第4章：引言

第5章：全球膠質母細胞瘤多形性治療市場

  • 市場概覽
  • 市場表現
  • 新冠疫情的影響
  • 市場區隔：依藥物類型分類
  • 市場區隔：依給藥途徑
  • 市場區隔：依分子類型分類
  • 市場區隔：按分銷管道
  • 市場區隔：按地區
  • 市場預測

第6章 市場區隔：依藥物類型

  • Temozolomide
  • Bevacizumab
  • Carmustine
  • 放射增敏劑
  • 其他

第7章 市場區隔：依給藥途徑

  • 口服
  • 腸外

第8章 市場區隔：依分子類型

  • 低分子
  • 生物製劑

第9章 市場區隔：按分銷管道

  • 醫院
  • 藥局
  • 其他

第10章 市場區隔：依地區分類

  • 北美洲
  • 歐洲
  • 亞太地區
  • 中東和非洲
  • 拉丁美洲

第11章 SWOT 分析

第12章：價值鏈分析

第13章：波特五力分析

第14章：價格分析

第15章 競爭格局

  • 市場結構
  • 大公司
  • 主要公司簡介
    • Sun Pharmaceutical Industries
    • Celldex Therapeutics
    • Pfizer
    • F. Hoffmann La Roche
    • Bristol-Myers Squibb
    • Teva Pharmaceuticals
    • Exelixis
    • Angiochem
    • Arbor Pharmaceuticals
Product Code: SR112026A1488

The global glioblastoma multiforme treatment market size reached USD 2.4 Billion in 2025. Looking forward, IMARC Group expects the market to reach USD 4.2 Billion by 2034, exhibiting a growth rate (CAGR) of 6.13% during 2026-2034.

Glioblastoma multiforme, also known as grade IV astrocytoma, is a malignant grade IV brain tumor that rapidly spreads within the brain cells and can also infect the nearby cells. Since it is characterized by rapid cell degeneration, it creates immense pressure on the brain resulting in severe headaches and seizures. Although the exact cause of the diseases is still unknown, several factors including rare hereditary disorders such as Turcot syndrome are believed to be its cause. It is one of the most lethal forms of brain cancer and is treatment-resistant in nature, wherein the patient has an extremely short survival period post-diagnosis. The current treatment procedure of the disease includes surgical resection, chemotherapy and radiation.

Increasing prevalence of oncological diseases and a growing geriatric population across the globe are among the key factors driving the market growth. Furthermore, the development of advanced treatment methods that counter the resistive properties of glioma stem cells is also positively influencing the market growth. Additionally, increasing research and development (R&D) activities in molecular biotechnology and gene therapy for cancer and related diseases have facilitated the development of various biological drugs. These drugs assist in diminishing the side-effects of the existing treatment methods, thus creating broader acceptance amongst patients. Moreover, initiatives undertaken by several governments across the globe to improve healthcare infrastructure, along with the rising awareness of the availability of various therapies, are further expected to create a positive outlook for the market.

KEY MARKET SEGMENTATION:

Breakup by Drug Type:

  • Temozolomide
  • Bevacizumab
  • Carmustine
  • Radiosensitizers
  • Others

Breakup by Route of Administration:

  • Oral
  • Parenteral

Breakup by Type of Molecule:

  • Small Molecule
  • Biologics

Breakup by Distribution Channel:

  • Hospitals
  • Pharmacies
  • Others

Breakup by Region:

  • North America
  • Europe
  • Asia Pacific
  • Middle East and Africa
  • Latin America

COMPETITIVE LANDSCAPE:

The report has also analysed the competitive landscape of the market with some of the key players being Sun Pharmaceutical Industries, Celldex Therapeutics, Pfizer, F. Hoffmann La Roche, Bristol-Myers Squibb, Teva Pharmaceuticals, Exelixis, Angiochem and Arbor Pharmaceuticals. IMARC Group's latest report provides a deep insight into the global glioblastoma multiforme treatment market covering all its essential aspects. This ranges from macro overview of the market to micro details of the industry performance, recent trends, key market drivers and challenges, SWOT analysis, Porter's five forces analysis, value chain analysis, etc. This report is a must-read for entrepreneurs, investors, researchers, consultants, business strategists, and all those who have any kind of stake or are planning to foray into the glioblastoma multiforme treatment market in any manner.

Key Questions Answered in This Report

1. What was the size of the global glioblastoma multiforme treatment market in 2025?

2. What is the expected growth rate of the global glioblastoma multiforme treatment market during 2026-2034?

3. What are the key factors driving the global glioblastoma multiforme treatment market?

4. What has been the impact of COVID-19 on the global glioblastoma multiforme treatment market?

5. What is the breakup of the global glioblastoma multiforme treatment market based on the route of administration?

6. What is the breakup of the global glioblastoma multiforme treatment market based on the type of molecule?

7. What is the breakup of the global glioblastoma multiforme treatment market based on the distribution channel?

8. What are the key regions in the global glioblastoma multiforme treatment market?

9. Who are the key players/companies in the global glioblastoma multiforme treatment market?

Table of Contents

1 Preface

2 Scope and Methodology

  • 2.1 Objectives of the Study
  • 2.2 Stakeholders
  • 2.3 Data Sources
    • 2.3.1 Primary Sources
    • 2.3.2 Secondary Sources
  • 2.4 Market Estimation
    • 2.4.1 Bottom-Up Approach
    • 2.4.2 Top-Down Approach
  • 2.5 Forecasting Methodology

3 Executive Summary

4 Introduction

  • 4.1 Overview
  • 4.2 Key Industry Trends

5 Global Glioblastoma Multiforme Treatment Market

  • 5.1 Market Overview
  • 5.2 Market Performance
  • 5.3 Impact of COVID-19
  • 5.4 Market Breakup by Drug Type
  • 5.5 Market Breakup by Route of Administration
  • 5.6 Market Breakup by Type of Molecule
  • 5.7 Market Breakup by Distribution Channel
  • 5.8 Market Breakup by Region
  • 5.9 Market Forecast

6 Market Breakup by Drug Type

  • 6.1 Temozolomide
    • 6.1.1 Market Trends
    • 6.1.2 Market Forecast
  • 6.2 Bevacizumab
    • 6.2.1 Market Trends
    • 6.2.2 Market Forecast
  • 6.3 Carmustine
    • 6.3.1 Market Trends
    • 6.3.2 Market Forecast
  • 6.4 Radiosensitizers
    • 6.4.1 Market Trends
    • 6.4.2 Market Forecast
  • 6.5 Others
    • 6.5.1 Market Trends
    • 6.5.2 Market Forecast

7 Market Breakup by Route of Administration

  • 7.1 Oral
    • 7.1.1 Market Trends
    • 7.1.2 Market Forecast
  • 7.2 Parenteral
    • 7.2.1 Market Trends
    • 7.2.2 Market Forecast

8 Market Breakup by Type of Molecule

  • 8.1 Small Molecule
    • 8.1.1 Market Trends
    • 8.1.2 Market Forecast
  • 8.2 Biologics
    • 8.2.1 Market Trends
    • 8.2.2 Market Forecast

9 Market Breakup by Distribution Channel

  • 9.1 Hospitals
    • 9.1.1 Market Trends
    • 9.1.2 Market Forecast
  • 9.2 Pharmacies
    • 9.2.1 Market Trends
    • 9.2.2 Market Forecast
  • 9.3 Others
    • 9.3.1 Market Trends
    • 9.3.2 Market Forecast

10 Market Breakup by Region

  • 10.1 North America
    • 10.1.1 Market Trends
    • 10.1.2 Market Forecast
  • 10.2 Europe
    • 10.2.1 Market Trends
    • 10.2.2 Market Forecast
  • 10.3 Asia Pacific
    • 10.3.1 Market Trends
    • 10.3.2 Market Forecast
  • 10.4 Middle East and Africa
    • 10.4.1 Market Trends
    • 10.4.2 Market Forecast
  • 10.5 Latin America
    • 10.5.1 Market Trends
    • 10.5.2 Market Forecast

11 SWOT Analysis

  • 11.1 Overview
  • 11.2 Strengths
  • 11.3 Weaknesses
  • 11.4 Opportunities
  • 11.5 Threats

12 Value Chain Analysis

13 Porters Five Forces Analysis

  • 13.1 Overview
  • 13.2 Bargaining Power of Buyers
  • 13.3 Bargaining Power of Suppliers
  • 13.4 Degree of Competition
  • 13.5 Threat of New Entrants
  • 13.6 Threat of Substitutes

14 Price Analysis

15 Competitive Landscape

  • 15.1 Market Structure
  • 15.2 Key Players
  • 15.3 Profiles of Key Players
    • 15.3.1 Sun Pharmaceutical Industries
    • 15.3.2 Celldex Therapeutics
    • 15.3.3 Pfizer
    • 15.3.4 F. Hoffmann La Roche
    • 15.3.5 Bristol-Myers Squibb
    • 15.3.6 Teva Pharmaceuticals
    • 15.3.7 Exelixis
    • 15.3.8 Angiochem
    • 15.3.9 Arbor Pharmaceuticals

List of Figures

  • Figure 1: Global: Glioblastoma Multiforme Treatment Market: Major Drivers and Challenges
  • Figure 2: Global: Glioblastoma Multiforme Treatment Market: Sales Value (in Billion USD), 2020-2025
  • Figure 3: Global: Glioblastoma Multiforme Treatment Market: Breakup by Drug Type (in %), 2025
  • Figure 4: Global: Glioblastoma Multiforme Treatment Market: Breakup by Route of Administration (in %), 2025
  • Figure 5: Global: Glioblastoma Multiforme Treatment Market: Breakup by Type of Molecule (in %), 2025
  • Figure 6: Global: Glioblastoma Multiforme Treatment Market: Breakup by Distribution Channel (in %), 2025
  • Figure 7: Global: Glioblastoma Multiforme Treatment Market: Breakup by Region (in %), 2025
  • Figure 8: Global: Glioblastoma Multiforme Treatment Market Forecast: Sales Value (in Billion USD), 2026-2034
  • Figure 9: Global: Glioblastoma Multiforme Treatment Industry: SWOT Analysis
  • Figure 10: Global: Glioblastoma Multiforme Treatment Industry: Value Chain Analysis
  • Figure 11: Global: Glioblastoma Multiforme Treatment Industry: Porter's Five Forces Analysis
  • Figure 12: Global: Glioblastoma Multiforme Treatment (Temozolomide) Market: Sales Value (in Million USD), 2020 & 2025
  • Figure 13: Global: Glioblastoma Multiforme Treatment (Temozolomide) Market Forecast: Sales Value (in Million USD), 2026-2034
  • Figure 14: Global: Glioblastoma Multiforme Treatment (Bevacizumab) Market: Sales Value (in Million USD), 2020 & 2025
  • Figure 15: Global: Glioblastoma Multiforme Treatment (Bevacizumab) Market Forecast: Sales Value (in Million USD), 2026-2034
  • Figure 16: Global: Glioblastoma Multiforme Treatment (Carmustine) Market: Sales Value (in Million USD), 2020 & 2025
  • Figure 17: Global: Glioblastoma Multiforme Treatment (Carmustine) Market Forecast: Sales Value (in Million USD), 2026-2034
  • Figure 18: Global: Glioblastoma Multiforme Treatment (Radiosensitizers) Market: Sales Value (in Million USD), 2020 & 2025
  • Figure 19: Global: Glioblastoma Multiforme Treatment (Radiosensitizers) Market Forecast: Sales Value (in Million USD), 2026-2034
  • Figure 20: Global: Glioblastoma Multiforme Treatment (Other Drug Types) Market: Sales Value (in Million USD), 2020 & 2025
  • Figure 21: Global: Glioblastoma Multiforme Treatment (Other Drug Types) Market Forecast: Sales Value (in Million USD), 2026-2034
  • Figure 22: Global: Glioblastoma Multiforme Treatment (Oral) Market: Sales Value (in Million USD), 2020 & 2025
  • Figure 23: Global: Glioblastoma Multiforme Treatment (Oral) Market Forecast: Sales Value (in Million USD), 2026-2034
  • Figure 24: Global: Glioblastoma Multiforme Treatment (Parenteral) Market: Sales Value (in Million USD), 2020 & 2025
  • Figure 25: Global: Glioblastoma Multiforme Treatment (Parenteral) Market Forecast: Sales Value (in Million USD), 2026-2034
  • Figure 26: Global: Glioblastoma Multiforme Treatment (Small Molecule) Market: Sales Value (in Million USD), 2020 & 2025
  • Figure 27: Global: Glioblastoma Multiforme Treatment (Small Molecule) Market Forecast: Sales Value (in Million USD), 2026-2034
  • Figure 28: Global: Glioblastoma Multiforme Treatment (Biologics) Market: Sales Value (in Million USD), 2020 & 2025
  • Figure 29: Global: Glioblastoma Multiforme Treatment (Biologics) Market Forecast: Sales Value (in Million USD), 2026-2034
  • Figure 30: Global: Glioblastoma Multiforme Treatment Market: Sales through Hospitals (in Million USD), 2020 & 2025
  • Figure 31: Global: Glioblastoma Multiforme Treatment Market Forecast: Sales through Hospitals (in Million USD), 2026-2034
  • Figure 32: Global: Glioblastoma Multiforme Treatment Market: Sales through Pharmacies (in Million USD), 2020 & 2025
  • Figure 33: Global: Glioblastoma Multiforme Treatment Market Forecast: Sales through Pharmacies (in Million USD), 2026-2034
  • Figure 34: Global: Glioblastoma Multiforme Treatment Market: Sales through Other Distribution Channels (in Million USD), 2020 & 2025
  • Figure 35: Global: Glioblastoma Multiforme Treatment Market Forecast: Sales through Other Distribution Channels (in Million USD), 2026-2034
  • Figure 36: North America: Glioblastoma Multiforme Treatment Market: Sales Value (in Million USD), 2020 & 2025
  • Figure 37: North America: Glioblastoma Multiforme Treatment Market Forecast: Sales Value (in Million USD), 2026-2034
  • Figure 38: Europe: Glioblastoma Multiforme Treatment Market: Sales Value (in Million USD), 2020 & 2025
  • Figure 39: Europe: Glioblastoma Multiforme Treatment Market Forecast: Sales Value (in Million USD), 2026-2034
  • Figure 40: Asia Pacific: Glioblastoma Multiforme Treatment Market: Sales Value (in Million USD), 2020 & 2025
  • Figure 41: Asia Pacific: Glioblastoma Multiforme Treatment Market Forecast: Sales Value (in Million USD), 2026-2034
  • Figure 42: Middle East and Africa: Glioblastoma Multiforme Treatment Market: Sales Value (in Million USD), 2020 & 2025
  • Figure 43: Middle East and Africa: Glioblastoma Multiforme Treatment Market Forecast: Sales Value (in Million USD), 2026-2034
  • Figure 44: Latin America: Glioblastoma Multiforme Treatment Market: Sales Value (in Million USD), 2020 & 2025
  • Figure 45: Latin America: Glioblastoma Multiforme Treatment Market Forecast: Sales Value (in Million USD), 2026-2034

List of Tables

  • Table 1: Global: Glioblastoma Multiforme Treatment Market: Key Industry Highlights, 2025 and 2034
  • Table 2: Global: Glioblastoma Multiforme Treatment Market Forecast: Breakup by Drug Type (in Million USD), 2026-2034
  • Table 3: Global: Glioblastoma Multiforme Treatment Market Forecast: Breakup by Route of Administration (in Million USD), 2026-2034
  • Table 4: Global: Glioblastoma Multiforme Treatment Market Forecast: Breakup by Type of Molecule (in Million USD), 2026-2034
  • Table 5: Global: Glioblastoma Multiforme Treatment Market Forecast: Breakup by Distribution Channel (in Million USD), 2026-2034
  • Table 6: Global: Glioblastoma Multiforme Treatment Market Forecast: Breakup by Region (in Million USD), 2026-2034
  • Table 7: Global: Glioblastoma Multiforme Treatment Market: Competitive Structure
  • Table 8: Global: Glioblastoma Multiforme Treatment Market: Key Players